Market Overview

Insmed Reports Added Data From ALS Phase 3 Trial For Adult Patients With Treatment Refractory NTM Lung Disease Caused By MAC: 'show 28% of patients who previously received 6 months of GBT alone achieved culture conversion'

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: FDA

 

Related Articles (INSM)